Skip to content
← Full study record

NCT00066703 · MORE INFO

Limitations, agreements, and source contact

Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer · Source last updated 2026-02-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
false
restrictive Agreement
false
point Of Contact
email
Heidi.Roschitzki@etop.ibcsg.org
organization
ETOP IBCSG Partners Foundation
phone
41 31 511 94 00
title
Dr. Heidi Roschitzki-Voser, PhD Head Trial Activities / Deputy Director
Complete source fields
certain Agreement
pi Sponsor Employee
false
restrictive Agreement
false
point Of Contact
email
Heidi.Roschitzki@etop.ibcsg.org
organization
ETOP IBCSG Partners Foundation
phone
41 31 511 94 00
title
Dr. Heidi Roschitzki-Voser, PhD Head Trial Activities / Deputy Director

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice